Researcher
Laurence Slembrouck
- Disciplines:Gynaecology and obstetrics, Nursing, Endocrinology and metabolic diseases
Affiliations
- Gynaecological Oncology (Division)
Member
From1 Nov 2016 → 30 Nov 2021
Projects
1 - 1 of 1
- Towards a better selection of systemic treatment for patients with ER-positive HER2-negative breast cancer: the use of prognostic and predictive markers in early and metastatic settingFrom1 May 2017 → 14 Oct 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 10
- Towards a better selection of systemic treatment for patients with ER-positive HER2-negative breast cancer: the use of prognostic and predictive markers in early and metastatic setting(2021)
Authors: Laurence Slembrouck, Patrick Neven, Isabelle Vanden Bempt, Beppe Floris
- Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2-early breast cancer(2021)
Authors: Laurence Slembrouck, Isabelle Vanden Bempt, Hans Wildiers, Ann Smeets, Anne-Sophie Van Rompuy, Chantal Van Ongeval, Caroline Weltens, Kevin Punie, Els Van Nieuwenhuysen, Sileny Han, et al.
Pages: 1297 - 1309 - Utility of p53 Immunostaining in Predicting Multigene Signatures Risk Category Results and Molecular Subtypes in a Series of Estrogen Receptor Positive and HER2 Negative Early Breast Cancers(2020)
Authors: Beppe Floris, Laurence Slembrouck, Mieke Van Bockstal, Laura Gadeyne, Anne-Sophie Van Rompuy, Cecile Colpaert, Sanne Verbeek, Claire Bourgain, Kevin Punie, Hans Wildiers, et al.
Pages: 142 - 144 - Utility of p53 Immunostaining in Predicting Multigene Signatures Risk Category Results and Molecular Subtypes in a Series of Estrogen Receptor Positive and HER2 Negative Early Breast Cancers(2020)
Authors: Beppe Floris, Laurence Slembrouck, Mieke Van Bockstal, Laura Gadeyne, Anne-Sophie Van Rompuy, Cecile Colpaert, Sanne Verbeek, Claire Bourgain, Kevin Punie, Hans Wildiers, et al.
Pages: 142 - 144 - Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris.(2019)
Authors: Laurence Slembrouck, Isabelle Vanden Bempt, Sara Vander Borght, Patrick Neven, Hans Wildiers, Ann Smeets, Ines Nevelsteen, Kevin Punie, Els Van Nieuwenhuysen, Sileny Han, et al.
Pages: 1557 - 1565 - Decentralization of Next-Generation RNA Sequencing-Based MammaPrint (R) and BluePrinti (R) Kit at University Hospitals Leuven and Curie Institute Paris(2019)
Authors: Laurence Slembrouck, Lauren Darrigues, Cecile Laurent, Lorenza Mittempergher, Leonie JMJ Delahaye, Isabelle Vanden Bempt, Sara Vander Borght, Liesbet Vliegen, Petra Sintubin, Virginie Raynal, et al.
Pages: 1557 - 1565 - Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast.(2019)
Authors: Kathleen Lambein, Ann Smeets, Laurence Slembrouck, Patrick Neven, Ines Nevelsteen, Caroline Weltens, Erik Van Limbergen, Rose Christiaens, Chantal Van Ongeval, Hans Wildiers, et al.
Pages: 550 - 559 - Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer(2019)
Authors: Laurence Slembrouck, Siel Olbrecht, Lynn Jongen, Hans Wildiers, Beppe Floris, Erik Van Limbergen, Caroline Weltens, Ann Smeets, Robert Paridaens, Ignace Vergote, et al.
Pages: 165 - 171 - Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer (vol 38, pg 1071, 2018)(2019)
Authors: Griet Hoste, Laurence Slembrouck, Lynn Jongen, Kevin Punie, Tom Matton, Sara Vander Borght, Isabelle Vanden Bempt, Joannes Menten, Hans Wildiers, Beppe Floris, et al.
Pages: 113 - 113 - Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer(2018)
Authors: Laurence Slembrouck, Lynn Jongen, Kevin Punie, Sara Vander Borght, Isabelle Vanden Bempt, Joannes Menten, Hans Wildiers, Beppe Floris, Patrick Neven
Pages: 1071 - 1075